Companies ›Healthcare ›LYEL.O

LYEL.O — NASDAQ Biotechnology

Lyel.O

$12,87

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

273,5M USD

P/E

—

EV / Rev

6 950,0x

Div yield

—

Op margin

-823 341,9 %

ROE

-99,3 %

Net margin

-794 858,1 %

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$12,97

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Lyell Immunopharma Inc operates as a biotechnology company within the Health Care sector, though specific revenue-generating activities are not detailed in the available data.

Business. Lyell Immunopharma Inc operates as a biotechnology company within the Health Care sector, though specific revenue-generating activities are not detailed in the available data.

Classification85 %

SectorHealth Care

Industry groupBiotechnology

Generated · model-assisted

Sell-side consensus

BUY7 analysts

6 buy0 hold1 sell

Avg 12m price target38,14

Analyst recommendations

7 analysts · consensus Buy

Buy6

Hold0

Sell1

12-month price target

38,14

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

7 analysts · indicative

Ownership→

BlackRock Institutional Trust Company, N.A.

largest disclosed fund holder

Profitability→

-99,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning LYEL.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to LYEL.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Lyell Immunopharma Inc operates as a biotechnology company within the Health Care sector, though specific revenue-generating activities are not detailed in the available data.

Classification85 %

SectorHealth Care

Industry groupBiotechnology

AI synthesis

GENERATED

Lyell Immunopharma maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds $60.2 million in cash and equivalents against total liabilities of $91.9 million, yielding a current ratio that suggests adequate short-term liquidity despite negative operating cash flow of $150.0 million. The market capitalization stands at $275.6 million, trading at a price-to-book ratio of 1.11, which indicates the market values the company close to its tangible book value of $248.2 million in total equity.

Profitability metrics reflect the pre-commercial or early-stage nature of the business, with a net loss of $274.4 million and an operating loss of $269.4 million. Return on equity is -99.3% and return on assets is -72.5%, significantly deviating from typical profitable cohort medians. The company generated only $36,000 in revenue, resulting in an extreme EV/Revenue multiple of 6,949.97 and a negative EV/EBITDA of -0.84, highlighting that current valuation is driven by future potential rather than current earnings.

Key takeaways

The company is debt-free with a price-to-book ratio of 1.11, trading near its tangible book value.
Significant net loss of $274.4 million and negative operating cash flow of $150.0 million highlight pre-commercial stage economics.
Analyst sentiment is positive with a mean price target of $38.14, implying substantial upside from the current $12.97 price.
Revenue is negligible at $36,000, resulting in an extreme EV/Revenue multiple of 6,949.97.
Low dilution and liquidity risk flags are present, but cash burn exceeds current cash reserves.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-05-06

Q1 2026 · Quarter highlights

Open report →

Revenue $2.0k, −71,4% YoY; Operating income +22,9% YoY.

Revenue$2.0k−71,4 % YoY

Operating income-$44.3M+22,9 % YoY

Net income-$24.2M+53,7 % YoY

Free cash flow-$21.9M+55,3 % YoY

EPS—

Operating cash flow-$38.5M+29,6 % YoY

Financials

Income statement

Revenue$2.0k

Gross profit—

Operating income-$44.3M

Net income-$24.2M

Margins

Gross margin—

Operating margin-2213050.0%

Net margin-1207650.0%

FCF margin-1095500.0%

Balance sheet

Total assets$350.6M

Total liabilities$77.0M

Total equity$273.7M

Cash & equivalents$90.8M

Long-term debt$0.00

Cash flow

Operating cash flow-$38.5M

CapEx-$89.0k

Free cash flow-$21.9M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue $2.0k, −71,4% YoY
▍Operating income +22,9% YoY
▍Net income +53,7% YoY
▍Free cash flow +55,3% YoY
▍Net margin -1207650.0%

Valuation TTM

Market price

$12,87

Market cap

$275.6M

Enterprise valueⓘ

$215.4M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

6950.0x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

1.1x

P / Tangible bookⓘ

1.1x

Tangible book

$248.2M

Net cashⓘ

$60.2M

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

-72.5%

ROEⓘ

-99.3%

Cash conversionⓘ

61.0%

CapEx / revenueⓘ

-1354.0%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 33 %

EPS

Consensus EPS

-7,64

Predicted surprise

-0,02

Beat probability

33 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-07-30 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-7,64
Revenue	—no estimate	—no estimate	9,750 USD
Operating income	—no estimate	—no estimate	-202,3M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 5 %

Probability

5 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-23 · 1,8× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution7 analysts

Strong buy1

Buy5

Hold0

Sell1

Strong sell0

12-month price target$38,14 · Median $44,00

Low $12,00High $49,00

Operating income · consensus-202,3M USD

EPS surprise

−110,2 %

reported vs consensus · miss

Revenue surprise

+269,2 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$12,00

Mean$38,14

Median$44,00

High$49,00

Spot$12,87

+196.4 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-823 341,9 %Bottom quartile

Net Margin-794 858,1 %Bottom quartile

ROE-99,3 %Bottom quartile

Capex / Rev-135 403,2 %Bottom quartile

D/E0,00Above median

Cash Conv0,61Below median

Corporate actions / M&A

M&A probabilityconf —

Probability

5 %

Base rate

3 %

Band

Moderate

180-day horizon · target 2027-01-23 · 1,8× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 524 750 sh12 grants12 insiders

Klausner RichardDirector · Option (right to buy) → Common StockAcquired 9 250 @ $13,22grant · 2026-06-10
NABEL ELIZABETH GDirector · Option (right to buy) → Common StockAcquired 9 250 @ $13,22grant · 2026-06-10
Ramachandra SumantDirector · Option (right to buy) → Common StockAcquired 9 250 @ $13,22grant · 2026-06-10
RIEFLIN WILLIAM JLDirector · Option (right to buy) → Common StockAcquired 9 250 @ $13,22grant · 2026-06-10
FRIEDMAN CATHYDirector · Option (right to buy) → Common StockAcquired 9 250 @ $13,22grant · 2026-06-10
BRAWLEY OTIS WDirector · Option (right to buy) → Common StockAcquired 9 250 @ $13,22grant · 2026-06-10
Bachleda MarkDirector · Option (right to buy) → Common StockAcquired 9 250 @ $13,22grant · 2026-06-10
Shah SmitalChief Fin. and Bus. Officer · Option (right to buy) → Common StockAcquired 140 000 @ $25,50grant · 2026-03-09
Hill Stephen J.Chief Operating Officer · Option (right to buy) → Common StockAcquired 65 000 @ $23,71grant · 2026-02-10
Lee Gary K.Chief Scientific Officer · Option (right to buy) → Common StockAcquired 50 000 @ $23,71grant · 2026-02-10
Seely LynnDirector, President and CEO · Option (right to buy) → Common StockAcquired 155 000 @ $23,71grant · 2026-02-10
Meltz Mark AGeneral Counsel · Option (right to buy) → Common StockAcquired 50 000 @ $23,71grant · 2026-02-10

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Reference data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Cash Conversion Ratio
operating_cash_flow / net_income
Market Price
input from market-data provider (delayed close or quote-shim mid)
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Market Cap
market_price * shares_outstanding_diluted

Source documents

Lyell Immunopharma, Inc. Market data — financials · 2026-07-30
reconciler_enqueue (reconciler) on LYEL.O · 2026-07-30
Lyell Immunopharma Inc Market data — analyst estimates · 2026-07-30
Lyell Immunopharma Inc Market data — ESG · 2026-07-30

Ownership & reference

Top holders

BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$20M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$25M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$2M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$3M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M

Leadership

Lynn SeelyPresident, Chief Executive Officer, Director

Insider activity

Net buying2 buys · 13 sellsnet $24,7M8 insiders · last 365d

Innovative Cellular Therapeutics Holdings Ltd10% owner · Common StockOther 38 500 · 2026-07-27
Innovative Cellular Therapeutics Holdings Ltd10% owner · Common StockOther 44 000 · 2026-07-27
Innovative Cellular Therapeutics Holdings Ltd10% owner · Common StockSold 10 @ $13,70$137 · 2026-07-17
Innovative Cellular Therapeutics Holdings Ltd10% owner · Common StockSold 10 @ $13,73$137 · 2026-07-16
Innovative Cellular Therapeutics Holdings Ltd10% owner · Common StockOther 76 000 · 2026-06-29
Innovative Cellular Therapeutics Holdings Ltd10% owner · Common StockOther 66 500 · 2026-06-15
Shook DavidChief Medical Officer · Common StockSold 1 977 @ $12,64$25K · 2026-06-10
Hill Stephen J.Chief Operating Officer · Common StockSold 89 @ $18,92$2K · 2026-05-11
Bulis Veronica SanchezVP, Corporate Controller · Common StockSold 217 @ $18,91$4K · 2026-05-11
Seely LynnDirector, President and CEO · Common StockSold 388 @ $18,91$7K · 2026-05-11
Lee Gary K.Chief Scientific Officer · Common StockSold 130 @ $18,92$2K · 2026-05-11
ARCH Venture Partners IX, LLC10% owner · Common StockBought 488 090 @ $25,61$12,5M · 2026-03-06
ARCH Venture Fund XIII, L.P.10% owner · Common StockBought 488 090 @ $25,61$12,5M · 2026-03-06
Hill Stephen J.Chief Operating Officer · Common StockSold 1 236 @ $23,39$29K · 2026-02-11
Seely LynnDirector, President and CEO · Common StockSold 7 455 @ $23,39$174K · 2026-02-11
Lee Gary K.Chief Scientific Officer · Common StockSold 1 671 @ $23,39$39K · 2026-02-11
Lee Gary K.Chief Scientific Officer · Common StockSold 147 @ $23,12$3K · 2026-02-10
Hill Stephen J.Chief Operating Officer · Common StockSold 109 @ $23,12$3K · 2026-02-10
Seely LynnDirector, President and CEO · Common StockSold 438 @ $23,12$10K · 2026-02-10
Hill Stephen J.Chief Operating Officer · Common StockOther 4 000 · 2026-02-09
Seely LynnDirector, President and CEO · Common StockOther 20 000 · 2026-02-09
Lee Gary K.Chief Scientific Officer · Common StockOther 4 000 · 2026-02-09

Short positioning

1.2Mshares short-0.2% vs prior

6.7days to cover

40.6%short of daily vol

246fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

LYEL.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob33 %Surprise-0,02M&A prob5 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Total assets (annual): USD 340.05MUnknown
Total liabilities (annual): USD 91.85MUnknown
Cash & equivalents (annual): USD 60.18MUnknown
Net income (annual): USD -274.45MUnknown
Revenue (annual): USD 36KUnknown
Operating income (annual): USD -269.4MUnknown
Capex (annual): USD 780KUnknown
Current assets (annual): USD 260.94MUnknown
EPS (basic) (annual): USD-PER-SHARES -16Unknown
Shareholders' equity (annual): USD 248.2MUnknown
Current liabilities (annual): USD 49.41MUnknown
Shares outstanding (annual): 21.25MUnknown
Total operating expenses (annual): USD 269.44MUnknown
Operating cash flow (annual): USD -150.02MUnknown
EPS (diluted) (annual): USD-PER-SHARES -16Unknown
Total assets (annual): USD 490.86MUnknown
Operating cash flow (annual): USD -162.39MUnknown
EPS (diluted) (annual): USD-PER-SHARES -26Unknown
Total operating expenses (annual): USD 358.82MUnknown
Cash & equivalents (annual): USD 105.6MUnknown
Shares outstanding (annual): 14.74MUnknown
Revenue (annual): USD 61KUnknown
Net income (annual): USD -342.99MUnknown
Capex (annual): USD 464KUnknown

Showing 24 of 30 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-27INSIDERInnovative Cellular Therapeutics Holdings Ltd transacted 38.5k sh — 10% owner

2026-07-27INSIDERInnovative Cellular Therapeutics Holdings Ltd transacted 44.0k sh — 10% owner

2026-07-17INSIDERInnovative Cellular Therapeutics Holdings Ltd sold 10 sh — 10% owner ~$0k

2026-07-16INSIDERInnovative Cellular Therapeutics Holdings Ltd sold 10 sh — 10% owner ~$0k

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-29INSIDERInnovative Cellular Therapeutics Holdings Ltd transacted 76.0k sh — 10% owner

2026-06-28 03:14 UTCHOLDERInstitutional holding changed

2026-06-28 03:14 UTCHOLDER2 institutional position changes flagged

2026-06-15 00:00 UTCINSIDER9 insider transactions — 2026-06 7 derivative

2026-06-15FILING8-K filing →

2026-06-15INSIDERInnovative Cellular Therapeutics Holdings Ltd transacted 66.5k sh — 10% owner

2026-06-10INSIDERShook David sold 2.0k sh — Chief Medical Officer ~$25k

2026-06-10INSIDERRIEFLIN WILLIAM JL acquired 9.2k sh Option (right to buy) — Director

2026-06-10INSIDERKlausner Richard acquired 9.2k sh Option (right to buy) — Director

2026-06-10INSIDERNABEL ELIZABETH G acquired 9.2k sh Option (right to buy) — Director

2026-06-10INSIDERRamachandra Sumant acquired 9.2k sh Option (right to buy) — Director

2026-06-10INSIDERBRAWLEY OTIS W acquired 9.2k sh Option (right to buy) — Director

2026-06-10INSIDERFRIEDMAN CATHY acquired 9.2k sh Option (right to buy) — Director

2026-06-10INSIDERBachleda Mark acquired 9.2k sh Option (right to buy) — Director

2026-05-11 00:00 UTCINSIDER4 insider transactions — 2026-05

2026-05-11INSIDERHill Stephen J. sold 89 sh — Chief Operating Officer ~$2k

2026-05-11INSIDERBulis Veronica Sanchez sold 217 sh — VP, Corporate Controller ~$4k

2026-05-11INSIDERSeely Lynn sold 388 sh — Director, President and CEO ~$7k

2026-05-11INSIDERLee Gary K. sold 130 sh — Chief Scientific Officer ~$2k

2026-05-06 16:05 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 0.0M · Net USD -24.2M

2026-05-06FILING10-Q filing →

2026-05-06FILING8-K filing →

2026-04-24FILINGDEF 14A filing →

2026-03-12 16:19 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 0.0M · Net USD -140.7M

2026-03-12 16:19 UTCEARNINGSAnnual results — FY 2026 Revenue USD 0.0M · Net USD -274.4M

2026-03-12FILING10-K filing →

2026-03-12FILING8-K filing →

2026-03-09 00:00 UTCINSIDER3 insider transactions — 2026-03 · net buy $25.0M 1 derivative

2026-03-09FILING8-K filing →

2026-03-09INSIDERShah Smital acquired 140.0k sh Option (right to buy) — Chief Fin. and Bus. Officer

Showing the 40 most recent of 72 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation TTM

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread